Medgenics Share Discussion Threads

[someuwin] 08/7/2011 08:35

Also, very useful that these can be put in an ISA.

[sicilian_kan] 08/7/2011 08:31

Yes, I think double the current share price would be justified at the moment, and if the Baxter deal is signed, the sky is the limit.

[someuwin] 08/7/2011 08:25

Looks like this one should go a lot higher.

[sicilian_kan] 08/7/2011 08:23

And another tick up.

[sicilian_kan] 08/7/2011 08:05

Nice movememnt today, still a long way to go.

[jammytass] 07/7/2011 16:17

yip rise well over due

[sicilian_kan] 07/7/2011 16:14

For what it is worth, my dummy MEDU sell was at 215p, i.e. at mid. V unusual to be able to sell at mid. Clearly the stock is in demand.

[sicilian_kan] 07/7/2011 16:03

Interesting. That should not be the case for an unrestricted stock as MEDU is. I can see why they might do it for MEDG. Worth having a word with them if you can. TDW is letting me buy and sell online.

[jammytass] 07/7/2011 16:02

Dealing online is not currently available for the stock you have selected. Please Contact Us if you want to deal by telephone.
barclays mmm

[sicilian_kan] 07/7/2011 15:58

No. I can buy and sell the unrestricted MEDU online.

[jammytass] 07/7/2011 15:56

is it still tel dealing only on aim for this?

[sicilian_kan] 07/7/2011 15:53

US stock now up 9%. This one will move eventually!

[sicilian_kan] 07/7/2011 15:27

Agreed. It would have been very easy for Baxter to force Medgenics to pay for the confirmatory test, unless the work Medgenics had was sufficiently compelling to justify them paying.

US stock up 8% now.

[jammytass] 07/7/2011 15:25

i agree at some point there will be a catch up, baxter would not be investing any more unless they are on a winner which i sure think this is.

[sicilian_kan] 07/7/2011 15:17

US stock now up 6%. Mid there is $4.25 on ADVFN and $4.315 on TDW.

Meanwhile at MEDG, we are trading at $2.93 (30% discount) and at MEDU $3.60 (15% discount).

At some stage these stocks will track each other, if only at bid point.

[sicilian_kan] 07/7/2011 14:55

US stock up another 4% today.

[sicilian_kan] 07/7/2011 14:13

Medgenics listed as one of "10 possible takeover targets" by Hoodless Brennan last Tuesday:



They have a 350p target price. In summary, and I paraphrase as the report is not written well, the Factor VIII progress (which could lead to Baxter signing a deal) could flush out a bid. As could the EPODURE progress.

[sicilian_kan] 07/7/2011 08:54

It is very surprising that this share has not yet taken off.

Yesterday's news confirmed that Medgenics have hit their Factor VIII targets and that all that is happening is a confirmatory test funded by Baxter.

We know that Baxter are likely to pay $2.5m just to negotiate exclusively (by end Sept 2010) and we know that the likely deal size thereafter if signed will be massive.

Baxter have just extended the agreement and funded this part of the tests. Why would they do this if they had no intention of signing the contract shortly?

Every indicator says that this deal will take off and we know if it does, it will dwarf the current market cap.

I'm just at a loss here as to the market.

[sicilian_kan] 06/7/2011 23:14

ProActive Article



Medgenics extends its collaboration with Baxter
3:24 pm by Ian Lyall

Medgenics (LON:MEDG, AMEX:MDGN) has extended its collaboration with US healthcare giant Baxter (NYSE:BAX), it was confirmed today.

The pair are working on a potential treatment for hemophilia, which uses Medgenics' Biopump platform that allows proteins to be released slowly and naturally in the body.

The new agreement will expire on September 30. At this point Baxter can exercise an exclusive six month option to negotiate a deal to commercialise the Biopump to deliver the Factor VIII blood clotting agent.

"During recent months Medgenics has made considerable progress with the performance of our Biopump technology, and we are delighted to be moving forward with our collaboration with Baxter, the global leader in hemophilia treatments," said Medgenics chief executive Andrew Pearlman.

"We look forward to completing these confirmatory studies and expect that they will validate the ability of our Biopump to produce clinically relevant levels of Factor VIII."

Medgenics' Biopump is a staggeringly simple invention, but one that could revolutionise the way certain drugs are delivered.

A tiny sliver of tissue smaller than a tooth pick is taken from a patient, modified to carry the gene to enable it to continuously produce the required protein. It is then re-injected into the body using the firm's proprietary DermaVac harvesting and implantation device.

The result is a system which produces and releases the required protein over a sustained period of time – clinical trials have shown it can last at least six months to a year.

And it is a truly personalised medicine as it uses the patient's own tissue to continuously make and deliver the protein in the way that person is used to receiving it.

Medgenics is developing three applications of the technology, which was the brainchild of Professor Ed Mitrani and Professor Amos Panet, of Jerusalem's Hebrew University.

They are for anaemia, hepatitis-C and haemophilia. However it appears to be a versatile platform technology that can be applied to almost any therapeutic protein, either registered or in development.

[sicilian_kan] 06/7/2011 23:04

US stock up just under 2% on today's news.

[sicilian_kan] 06/7/2011 18:15

Thanks jt. It confirms what Andy Pearlman was saying at ProActive, about the progress that had been madeon Factor VIII. Good to get the formal confirmation and the collaboration extension externally validating it.

[jammytass] 06/7/2011 18:08

n

RNS
RNS Number : 8915J
Medgenics Inc
06 July 2011








MEDGENICS EXTENDS COLLABORATION WITH BAXTER ON DEVELOPMENT OF FACTOR VIII BIOPUMP

MISGAV, Israel and VIENNA, Va. (July 06, 2011) - Medgenics, Inc. (NYSE Amex: MDGN and AIM: MEDU, MEDG) announces an extension of its agreement with Baxter Healthcare Corporation for the joint development of the Factor VIII Biopump.

Under the extension, confirmatory studies will be conducted implanting Factor VIII Biopumps in mice. Baxter will bear the costs of these studies including the preparation and delivery of the necessary Biopumps. During the extended agreement, which will expire by September 30, 2011, Baxter has the opportunity, to exercise an exclusive option for 6 months to negotiate with Medgenics an agreement for commercialization of the Biopump Factor VIII technology.

"During recent months Medgenics has made considerable progress with the performance of our Biopump technology, and we are delighted to be moving forward with our collaboration with Baxter, the global leader in hemophilia treatments," stated Andrew L. Pearlman, Ph.D., President and CEO of Medgenics. "We look forward to completing these confirmatory studies and expect that they will validate the ability of our Biopump to produce clinically relevant levels of Factor VIII."

[rodozz] 06/7/2011 15:44

Whilst working with these behemoths is always difficult and delays inevitable it does look promising

[sicilian_kan] 06/7/2011 15:35

Nomura estimate that a pre-clinical deal for hemophilia would be around:

$2.5m for exclusivity negotiation period
$20m up front for signing
$75m at end of Phase I/IIa, entering Phase IIb
$100m at end of Phase IIb, entering Phase III
$100m at end of Phase III, entering regulatory submission
$120m on regulatory approval.

This does not include sales milestones or royalties, just the trial milestones.